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RGFP, Renilla green fluorescent protein; GPCR, G protein-coupled receptors; 
ßARR, ßarrestin; V2R, vasopressin 2 receptor ; MT1, melatonin 1 receptor; AVP, 
Argininine Vasopressine.
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Abstract 
 
We report highly sensitive Bioluminescence Resonance Energy Transfer 
(BRET) assays with optimized donor/acceptor couples. We combined the 
energy donors Renilla luciferase (Rluc) and the Rluc8 variant with the energy 
acceptors yellow fluorescent protein (YFP), the YPet variant and the Renilla 
green fluorescent protein (RGFP). Different donor/acceptor couples were 
tested in well-established assays measuring ligand-induced ß-arrestin 
(ßARR) intramolecular rearrangements and recruitment to G protein-
coupled receptors (GPCRs). We show increased sensitivity with Rluc8/YPet 
and Rluc8/RGFP couples and measured previously undetectable BRET 
signals. These tools improve existing ßARR assays and offer new options for 
the development of future BRET assays.  
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1. Introduction 
 
BRET is a natural phenomenon occurring in several marine organisms. In 1999, 
Xu et al. first applied BRET to the detection of protein-protein interactions in 
intact cells [1]. This initial version, nowadays called BRET1, relies on the Rluc 
energy donor and its substrate, coelenterazine h, and the YFP energy acceptor. 
The overlap between the donor and acceptor energy spectra is substantial, 
resulting in a relatively high background signal that needs to be carefully 
controlled [2].  In contrast, the BRET2 version uses Rluc in the presence of the 
blue-shifted substrate coelenterazine 400A and the GFP10 variant that shows a 
blue-shifted absorption spectrum [3, 4]. Despite improved spectral resolution in 
the BRET2 version, BRET1 is still the most widely used method due to its higher 
sensitivity (>100X higher luminescence signals) [5] allowing BRET 
measurements at physiological protein expression levels [6].  
The primary goal of this study was to further improve the BRET1 version by 
testing new donor/acceptor couples. We compared the original energy donor Rluc 
with the recently described Rluc8 variant, which differs by eight mutations from 
Rluc. Rluc8 was selected for its higher stability and quantum yield [7] and was 
successfully applied to BRET imaging in a BRET2 setting [8]. Furthermore, we 
compared the original YFP with the YPet variant and the recently cloned RGFP. 
YPet was optimized for enhanced fluorescence resonance energy transfer (FRET) 
in a tandem CFP-YFP fusion protein [9], an experimental setting closely 
resembling the Rluc/YFP BRET couple. For RGFP, an improved energy transfer 
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efficiency was reported in BRET2 assays but only if the N-terminus of RGFP was 
free, considerably restricting the use of RGFP in BRET assays [10].  
GPCRs play a central role in the signal transduction of an enormous array of 
biological stimuli primarily through their coupling to heterotrimeric G proteins. 
GPCR activation initiates their feedback desensitization, which is mostly 
mediated by GPCR kinases (GRKs) and ßARR proteins. ßARRs can also act as 
scaffolds, linking GPCRs to mitogen-activated protein kinase signaling pathways 
[11]. Because ßARRs bind only the activated, phosphorylated form of the 
receptor, BRET assays using ßARRs as biosensors for GPCR activation were 
widely developed in the last decade [12, 13]. 
In order to test the new BRET couples described above, we chose two well-
established BRET assays used to monitor agonist-promoted interactions upon 
GPCR activation: the ligand-induced ßARR intramolecular rearrangement and the 
ligand-induced ßARR recruitment to GPCRs. 
 
2. Materials and Methods 
2.1. Compounds 
Arginine vasopressin (AVP) was purchased from Calbiochem/Merck (Notingham, 
UK), melatonin from VWR (Fontenay sous Bois, France). The d(CH2)5[D-
Tyr(Et)2, Ile4, Eda9]AVP compound was provided by Dr. M. Manning (Toledo, 
Ohio, USA). 
 
2.2. Construction of fusion proteins 
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The coding sequences for humanized Rluc, YFP, and Renilla mullerie GFP 
(RGFP) were obtained by PCR amplification from previously described pcDNA3-
OBR-Rluc, pcDNA3-OBR-YFP [14] and pCMV-h-RM RGFP vectors (Prolume, 
Arizona USA). The Rluc8 and YPet variants were generated by multi-site 
mutagenesis (Promega, Charbonnières-les-Bains, France) from the Rluc and YFP 
sequences. Tandem Acceptor-Rluc-Flag and Acceptor-Rluc8-Flag fusions were 
generated by PCR by inserting the AENLYFQGA linker sequence between 
acceptors and donors and adding a Flag epitope (DYKDDDDK) before the Stop 
codon. Tandem Flag-Rluc-RGFP and Flag-Rluc8-RGFP fusion proteins contain 
the same linker between donors and RGFP and the Flag epitope was inserted after 
the Start codon of the donors. 
The human V2R coding region was cloned in frame with the Rluc coding region 
to obtain the V2R-Rluc construct. The V2R-Rluc8 construct was obtained by 
replacing Rluc by Rluc8. Both constructs contain a PVAT linker sequence.  
Rluc and YFP of the previously described Rluc-ßARR2-YFP vector [13] were 
replaced by Rluc8, YPet and RGFP, respectively. The linker between donors and 
ßARR2 is composed of the following amino acids 
GDLRRALENSHASAGYQACGTGS and the linker between ßARR2 and the 
acceptors is CLEDPRVPVAT.  
Acceptor-ßARR2 fusion proteins were obtained by fusing the coding region of 
YFP, YPet or RGFP in frame with that of rat ßARR2 without linker.  
Page 7 of 31
Wiley-VCH
Biotechnology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 7
MT1-Rluc8 construct was obtained by replacing Rluc by Rluc8 from a previously 
described MT1-Rluc vector [15]. MT1-Rluc and MT1-Rluc8 contained the same 
linker sequence (VWDPPVAT) between human MT1 and the donor. 
 
2.3. Cell culture and transfections 
HEK 293T cells were grown in complete medium (Dulbecco’s modified Eagle’s 
medium supplemented with 10% (v/v) fetal bovine serum, 4.5g/L glucose, 
100U/mL penicillin, 0.1mg/mL streptomycin and 1mM glutamine) (Invitrogen, 
CA). Transient transfections were performed using JetPEI (Polyplus Transfection, 
France), or Fugene6 HD (Roche, Basel, Switzerland), according to manufacturer’s 
instructions. 
For Donor/Acceptor fusion protein BRET assays and corresponding separate co-
expressed soluble proteins, HEK 293T cells, which do not express endogenous V2 
and MT1 receptors, were transfected with 2 to 10µg of the different plasmids.  
For the double-brilliance ßARR BRET assay, wild-type HEK 293T cell 
transiently expressing myc-V2R or HEK 293 cells stably expressing Flag-MT1 
[16] were seeded in 6-well plates and transiently transfected with 500ng of Rluc-
βARR-YFP, Rluc-βARR-YPet, Rluc-βARR-RGFP, Rluc8-βARR-YFP, Rluc8-
βARR-YPet or Rluc8-βARR-RGFP expression vectors. 24h post-transfection, 
cells were transferred into 96-well plates and left another 24h before BRET 
measurements.  
For the ßARR recruitment BRET assay, HEK293T cells were seeded in 10 cm 
dishes and transiently transfected with 1500ng and 750ng of myc-V2R-Rluc and 
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myc-V2R-Rluc8, respectively. 4h post-transfection cells were transferred into 12-
well plates, and transfected 24h later with increasing amounts of YFP-βARR, 
YPet-βARR and RGFP-βARR expression plasmids. Cells were then transferred 
into 96-well plates and left another 24h before BRET measurements. 
Concentration-response curves were performed in presence of saturating amounts 
of YFP-βARR, YPet-βARR and RGFP-βARR expression plasmids. 
Measurements were performed 15 min after agonist addition. 
 
2.4. BRET experiments 
 
For Donor-Acceptor fusion proteins and the corresponding separate soluble forms, 
cytoplasmic extracts were prepared 48h post-transfection as described previously 
[10], diluted and submitted to BRET measurements in the presence of 5µM 
coelenterazine h (Interchim, Montluçon, France). 
For the double-brilliance ßARR2 and ßARR2 recruitment assays, cells were 
washed once with PBS 48h post-transfection, and coelenterazine h substrate was 
added at a final concentration of 5µM and left for 10min at RT. Cells were then 
stimulated by a saturating concentration of ligands for 15 min (double-brilliance 
ßARR2) or 5 min (ßARR2 recruitment). Arginine vasopressin (AVP) and 
melatonin were used as agonist for V2R and MT1 experiments, respectively.  
BRET readings were performed using a lumino/fluorometer (Mithras; Berthold 
technologies, France) allowing sequential integration of luminescence with three 
filter settings (Rluc filter, 485 ± 10 nm; YFP (and YPet) filter, 530 ± 12.5 nm, 
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RGFP filter, 515 ± 10 nm). Emission signals at 530 or 515 nm were divided by 
emission signals at 485 nm. The difference between this emission ratio obtained 
with donor and acceptor fused or co-expressed and that obtained with the donor 
protein expressed alone was defined as the BRET ratio. Results are expressed in 
milliBRET units (mBU) corresponding to the BRET ratio multiplied by 1000. 
Donor saturation curves and determination of maximal BRET values were 
described previously [17]. 
 
2.5. Western Blot 
Proteins were separated by 10% SDS-PAGE and immunoblot analysis was carried 
out with the following antibodies: Mouse-monoclonal anti-Flag M2 (SIGMA, 
MO), mouse monoclonal anti-myc (Santa Cruz, CA), mouse monoclonal anti-
Renilla Luciferase (Chemicon International, CA), rabbit polyclonal anti-βARR 
(SIGMA, MO) and rabbit polyclonal anti-α-tubulin (Sigma, MO). 
Immunoreactivity was revealed using IRDye infrared secondary antibodies using 
the LI-COR Odyssey infrared imaging system (Courtaboeuf, France). 
 
3. Results 
 
3.1 BRET efficiency of tandem fusion proteins 
 
We first generated a series of N-Acceptor-Donor-C fusion proteins composed of a 
N-terminal acceptor, a common linker sequence and a C-terminal donor. 
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Expression of equivalent amounts of fusion proteins in HEK 293T cells revealed 
the expected strong BRET for direct fusion proteins (Fig. 1A). Dilutions of these 
samples up to 64 fold showed the expected stability of the BRET ratio (data not 
shown). On the other hand, co-expression of the new donor/acceptor couples as 
separate proteins resulted in negligible BRET signals (0-30 mBU) demonstrating 
their suitability for the study of protein-protein interactions (Fig. 1A). BRET 
values were highest for YPet fusion proteins followed by YFP and RGFP fusion 
proteins and were always higher for Rluc8 fusion proteins as compared to the 
corresponding Rluc fusion proteins. The use of RGFP in BRET has been reported 
to be sensitive to its position in the fusion protein (N-terminal vs. C-terminal 
fusion) [10].  We therefore tested N-Donor-RGFP-C fusion proteins with RGFP 
located at the C-terminus. A robust BRET signal that was higher than that of N-
RGFP-Donor-C fusion proteins was observed (Fig. 1B). Taken together YPet 
fusion proteins showed highest BRET signals, whereas BRET signals for RGFP 
and YFP fusion proteins were comparable. 
 
3.2. Improved BRET signals with Rluc8/YPet and Rluc8/RGFP couples when 
monitoring ligand-induced ßARR2 intramolecular conformational changes 
 
We next generated intramolecular BRET biosensors based on the recently 
described double-brilliance ßARR assay [13]. This assay monitors the 
conformational rearrangement of ßARR2 bringing its N-terminus and C-terminus 
into closer proximity upon recruitment to agonist activated GPCRs. Equivalent 
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amounts of the indicated N-Donor-ßARR2-Acceptor-C fusion proteins, as 
indicated by Western Blot, were transiently expressed in myc-V2 vasopressin 
receptor (myc-V2R)-expressing cells, known to recruit ßARR2. BRET values 
were monitored for 15 min in the absence or presence of a saturating 
concentration of the V2R agonist AVP (10µM). Maximal BRET signals were 
generally observed as early as 4 min after agonist addition, indicating that the 
double-brilliance fusion constructs are functional (Supplementary Fig. 1B). 
Comparison of agonist-induced BRET after 15 min of stimulation showed 
enhanced induced-BRET for N-Rluc8-ßARR2-YPet-C and N-Rluc8-ßARR2-
RGFP-C (2-3 fold, respectively) when compared with other constructs (Fig. 2A).  
Agonist concentration-response curves were performed showing BRET EC50 
values ranging 75 +/- 45 nM and 79 +/- 29 nM for N-Rluc8-βARR2-YPet-C and 
N-Rluc8-βARR2-RGFP-C constructs, respectively (Fig. 2B). Similar values were 
obtained for the other double-brilliance fusion constructs (data not shown). 
We then expressed the different ßARR2 fusion proteins in HEK 293T cells stably 
expressing Flag-MT1 melatonin receptors a GPCR whose ßARRs recruitment is 
difficult to monitor using the classical Rluc-ßARR2-YFP fusion protein (Fig. 2A). 
Whereas agonist-induced BRET signals (10 µM melatonin) were barely 
detectable for all Rluc-containing fusions, BRET signals became clearly 
detectable as early as 2 min after agonist addition for N-Rluc8-ßARR2-YPet-C 
and N-Rluc8-ßARR2-RGFP-C constructs (Fig. 2A) (Supplementary Fig. 1C). 
Comparable BRET EC50 values of 6.3 +/- 3.7 nM and 8.2 +/- 4.9, were obtained 
Deleted: dose
Page 12 of 31
Wiley-VCH
Biotechnology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12
for melatonin using N-Rluc8-ßARR2-YPet-C and N-Rluc8-ßARR2-RGFP-C 
constructs, respectively (Fig. 2C).  
Expression of equivalent amounts of the indicated N-Donor-ßARR2-Acceptor-C 
fusion proteins in HEK 293T cells in the absence of V2R and MT1 did not result 
in agonist-induced BRET signals, demonstrating the specificity of the assay (data 
not shown). Taken together, these results show that the Rluc8/YPet and 
particularly the Rluc8/RGFP couple significantly amplify weak and previously 
undetectable BRET signals of the intramolecular ßARR2 biosensor.  
 
3.3. Improved BRET signals with Rluc8/YPet and Rluc8/RGFP couples when 
monitoring ligand-induced ßARR2 recruitment to GPCR 
 
We further analyzed the donor/acceptor couples in the ßARR2 recruitment assay 
[12, 18]. Similar amounts of V2R-Rluc or V2R-Rluc8 C-terminal fusion proteins 
were co-expressed with increasing amounts of N-Acceptor-ßARR2-C fusion 
constructs and ligand-induced BRET was measured at maximal ßARR2 
recruitment (5 min after agonist addition). BRET donor saturation curves were 
generated in the absence or presence of AVP (10µM) as previously described [14, 
19] to determine BRETmax values that correspond to the saturation of all donor 
molecules by acceptor molecules (Fig. 3)(Supplementary Fig. 2). All couples 
showed significant agonist-induced BRET signals with highest BRETmax values 
for the V2R-Rluc8/ N-RGFP-ßARR2-C couple (Table 1). No significant ligand-
induced BRET signals were observed in the presence of the V2R antagonist 
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Vd(CH2)5[D-Tyr(Et)2, Ile4, Eda9]AVP (Table 1)(Supplementary Fig. 2). Basal 
BRET values were highest for the V2R-Rluc8/ N-RGFP-ßARR2-C couple 
indicating the increased sensitivity of this couple to monitor basal ßARR2 
recruitment. This recruitment is specific as expression of V2R-Rluc8 in the 
presence of soluble RGFP gave negligible BRET values (Supplementary Fig. 
2A). Basal ßARR2 recruitment to V2R has been observed recently [10]. 
Moreover, agonist concentration-response curves, in the presence of saturating 
amounts of acceptors, were performed showing BRET EC50 ranging from 5 to 15 
nM AVP for the different N-Acceptor-βARR2-C constructs (data not shown).  
We then measured ßARR2 recruitment to MT1-Rluc and MT1-Rluc8. Whereas the 
recruitment to MT1-Rluc was undetectable, recruitment to MT1-Rluc8 became 
detectable in combination with YPet and RGFP further demonstrating the 
superiority of these new BRET couples. 
 
4. Discussion 
 
The ßARR recruitment assay has become increasingly popular to monitor GPCR 
activation. Since the development of the BRET technology in 1999 and the first 
ßARR assay in 2000, several improvements have been reported to increase 
signaling amplitude and stability [20] [21]. Here, we focused on improving the 
most sensitive and widely used BRET1 version by combining recently developed 
energy donors (Rluc, Rluc8) and acceptors (YFP, YPet, RGFP) in a systematic 
manner. By using two well-established BRET assays measuring ßARR2 
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intramolecular rearrangements and recruitment to GPCRs, we show that 
Rluc8/YPet(RGFP) couples significantly increase the sensitivity of these assays, 
allowing the detection of previously undetectable BRET signals. 
We observed that Rluc8 and Rluc8 fusion proteins emit 2-4 times more light than 
the corresponding Rluc proteins expressed at equivalent levels as previously 
reported (Supplementary Fig. 3) [7, 8, 21]. The higher luminescence intensity of 
Rluc8 implies a more efficient acceptor excitation and re-emission and the 
possibility to further decrease protein expression levels to physiologically relevant 
levels. In agreement with previous FRET experiments using YPet-CFP fusion 
proteins, we show that YPet is a better BRET acceptor than YFP [9]. Whereas the 
energy transfer efficiency in BRET assays is typically low, Molinari et al. recently 
reported the striking observation that RGFP in combination with Rluc can 
generate close to 100% energy transfer associated with a dramatic increase in 
acceptor light output [10]. The underlying molecular basis of this phenomenon, 
which is only observed when the N-terminus of RGFP is free, remains unclear. By 
using N-terminal RGFP fusion proteins in two independent assays (RGFP-Rluc 
tandem fusion protein and GPCR-Rluc/ RGFP-ßARR2 couple), we were unable to 
confirm these observations. Indeed, no major difference in BRET signals 
generated by YFP- and RGFP-containing fusion proteins were observed. 
Accordingly, Rluc light output did not vary significantly with increased BRET 
(not shown). The reason for this discrepancy remains currently unknown and 
warrants further studies. We furthermore noted that BRET values obtained with 
RGFP fusion proteins may be subject to some variation as illustrated by the 
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scattering of BRET values obtained in the donor saturation experiment with 
RGFP-ßARR2 and V2R-Rluc8 (Supplementary Fig. 2). These results indicate  
that RGFP is a highly sensitive energy acceptor. RGFP can be therefore 
considered as an interesting BRET acceptor, which can result in superior BRET 
values, particularly when compared to YFP. The data show that the use of RGFP 
is not restricted to N-terminal fusion proteins, which considerably increases its 
attractiveness for the BRET assay. More importantly, RGFP shows improved 
sensitivity compared to YFP when combined with the Rluc8 variant.  
Overall, Rluc8/YPet and Rluc8/RGFP couples provide superior results compared 
to the classical Rluc/YFP couple. According to the data obtained in the ßARR2 
recruitment assay, these BRET couples primarily increase the overall sensitivity 
of the assay whereas the signal-to-noise ratio appears to be comparable for all 
combinations (3-5 fold increase between basal and AVP-induced BRET signals) 
(Table 1). Despite obvious conceptual advantages of the double brilliance ßARR2 
biosensor such as the use of unmodified wild-type GPCR and high assay stability 
due to the fixed donor/acceptor ratio, the assay is not broadly used in the literature 
[13, 22]. The low amplitude of ligand-induced BRET signals is one of these 
reasons. The increased sensitivity observed with the new donor/acceptor 
combinations clearly increases the attractiveness of the assay. A widespread 
application to monitor ßARR-dependent signaling events in the context of ligand-
biased signaling can be anticipated.  
Several ßARR activation/recruitment assays have been developed over the years, 
particularly for high-throughput screening purposes. Each of these assays has its 
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own advantages and disadvantages. BRET assays measure ligand-induced signals. 
This is not the case for the fluorescence-based assay that monitors the cellular 
localization of βARR-EGFP fusion proteins [23, 24]. If the changes in ßARR 
localization following agonist stimulation are small, data analysis may become 
difficult. The TANGO (Invitrogen corporation) ßARR assay that is coupled to a 
protease-mediated transcriptional reporter gene readout shows excellent assay 
sensitivity, due to the sensitive reporter gene read-out [25]. However, a high 
number of false positives can be anticipated in a high-throughput screening assays 
due to multiple intermediates between receptor activation and gene transcription 
initiation. BRET assays do not suffer from these potential drawbacks as receptor 
activation is closely coupled to the final read-out. This is also the case of the 
recently described enzyme fragment complementation assay for ßARR, now 
commercially available as PathHunter technology from DiscoverX [26]. 
Conditions for successful enzyme complementation might be more demanding 
than conditions for successful energy transfer leading potentially to the detection 
of less compounds compared to BRET assays. Relatively low signals can be 
considered as one of the major disadvantages of ßARR-based BRET assays. The 
new donor-acceptor couples presented here improve this parameter, in particular 
in the double-brilliance assay. 
In conclusion, the new BRET1 couples, Rluc8 and YPet/RGFP clearly widen the 
application of ßARR BRET assays as previously weakly detectable or even 
undetectable BRET signals are now reliably detected. These new BRET couples 
are likely to become of general interest for the detection of protein-protein 
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interactions in intact cells at physiological expression levels. Enhanced ligand-
promoted BRET signals might also be beneficial for high-throughput screening 
procedures. 
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Legends to figures: 
Figure 1: BRET measured with different donor/acceptor couples. (A) 
Donor/acceptor proteins were co-transfected () or transfected as N-Donor-
Acceptor-C tandem proteins () and BRET was measured. (B) Comparison of 
BRET measured for N-Donor-RGFP-C and N-RGFP-Donor-C fusion proteins. 
n=5 independent experiments. 
 
Figure 2: Monitoring of ligand-induced ßARR2 intramolecular rearrangement. 
(A) Bar Charts showing the intramolecular rearrangement of the indicated ßARR2 
double-brilliance constructs upon recruitment to agonist activated V2R () or 
MT1 () in HEK 293T cells (15 min stimulation with agonist); n=4 independent 
experiments. (B) AVP concentration-response curves showing for N-Rluc8-
βARR2-YPet-C () and N-Rluc8-βARR2-RGFP-C () (n=2). (C) Melatonin 
concentration-response curves for N-Rluc8-βARR2-YPet-C () and N-Rluc8-
βARR2-RGFP-C () (n=2). Expression of ßARR2 was verified by western 
blotting using anti-ßARR antibodies. Further experimental details and controls are 
shown in Supplementary Fig. 1. A, acceptor; C, C-terminus; D, donor; N, N-
terminus; α-tub, α-tubulin.  
 
Figure 3: BRET measured with the ßARR recruitment assay. Agonist-induced 
recruitment of the indicated ßARR2 fusion constructs to V2R-Rluc or V2R-Rluc8 
() (10 µM AVP, 5 min), and MT1-Rluc or MT1-Rluc8 () (10 µM melatonin, 5 
min). Expression of V2R-Rluc and V2R-Rluc8 was verified by western blot using 
Deleted: dose-
Deleted: dose-
Page 21 of 31
Wiley-VCH
Biotechnology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 21
anti-Rluc antibodies (that recognize Rluc and Rluc8 equally well, data not 
shown). Ligand-induced BRET was defined as the difference between BRETmax 
values obtained from donor saturation curves +/- ligand. Saturation curves and 
further controls are shown in Supplementary Fig. 2; α-tub, α-tubulin. n=4 
independent experiments. 
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Table 1: BRET ßARR2 recruitment assay.  
 
BRETmax and fold stimulation values following agonist stimulation.  
BRETmax values were determined as described in the “Material and Methods” 
section and ligand-induced BRET (shown in Fig. 2) was defined as the difference 
between BRETmax values in the absence and presence of ligand. BRET was 
measured in the absence and presence of the V2R agonist AVP and V2R 
antagonist Vd(CH2)5[D-Tyr(Et)2, Ile4, Eda9]AVP. The fold induction values are 
expressed as the ratio of  the agonist induced Bretmax/Basal Bretmax. 
 
 
 
 BRET max (mBU)  Fold stimulation 
 Basal AVP Antagonist  AVP/Basal 
V2R-Rluc/YFP-bARR2 9±1 35±3 12±1  3.9 
V2R-Rluc/Ypet-bARR2 10±2 59±5 10±3  5.5 
V2R-Rluc/RGFP-bARR2 9±1 37±3 13±1  4.1 
V2R-Rluc8/YFP-bARR2 13±1 52±4 13±1  4.0 
V2R-Rluc8/Ypet-bARR2 16±1 67±4 20±2  4.2 
V2R-Rluc8/RGFP-bARR2 58±4 192±18 65±5  3.3 
V2R-Rluc8/RGFP 6±1 4±1 3±1  0.7 
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Figure 1: BRET measured with different donor/acceptor couples. (A) Donor/acceptor proteins were 
co-transfected (ο) or transfected as N-Donor-Acceptor-C tandem proteins (<) and BRET was 
measured. (B) Comparison of BRET measured for N-Donor-RGFP-C and N-RGFP-Donor-C fusion 
proteins. n=5 independent experiments.  
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Figure 2: Monitoring of ligand-induced ßARR2 intramolecular rearrangement. (A) Bar Charts 
showing the intramolecular rearrangement of the indicated ßARR2 double-brilliance constructs upon 
recruitment to agonist activated V2R (ο) or MT1 (<) in HEK 293T cells (15 min stimulation with 
agonist); n=4 independent experiments. (B) AVP dose-response curves showing for N-Rluc8-βARR2-
YPet-C (ϒ) and N-Rluc8-βARR2-RGFP-C (ο) (n=2). (C) Melatonin dose-response curves for N-Rluc8-
βARR2-YPet-C (ϒ) and N-Rluc8-βARR2-RGFP-C (ο) (n=2). Expression of ßARR2 was verified by 
western blotting using anti-ßARR antibodies. Further experimental details and controls are shown in 
Supplementary Fig. 1. A, acceptor; C, C-terminus; D, donor; N, N-terminus; α-tub, α-tubulin.  
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Figure 3: BRET measured with the ßARR recruitment assay. Agonist-induced recruitment of the 
indicated ßARR2 fusion constructs to V2R-Rluc or V2R-Rluc8 (ο) (10 µM AVP, 5 min), and MT1-Rluc 
or MT1-Rluc8 (<) (10 µM melatonin, 5 min). Expression of V2R-Rluc and V2R-Rluc8 was verified by 
western blot using anti-Rluc antibodies (that recognize Rluc and Rluc8 equally well, data not 
shown). Ligand-induced BRET was defined as the difference between BRETmax values obtained 
from donor saturation curves +/- ligand. Saturation curves and further controls are shown in 
Supplementary Fig. 2; α-tub, α-tubulin. n=4 independent experiments.  
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Supplementary Figures: 
 
Supplementary Fig. 1: Supplementary data of donor/acceptor tandem fusion protein BRET assay and 
double-brilliance ßARR2 biosensors shown in Fig. 1. (A) Expression of Myc-V2R and Flag-MT1 in Fig. 
1B was verified by western blot using anti-Myc and anti-Flag antibodies. (B) Kinetics of AVP- and 
melatonin-promoted BRET changes of the indicated double-brilliance ßARR2 biosensors in HEK 293T 
cells. AVP (V2R agonist) and melatonin (MT1 agonist) were used at 10µM. NT, non-transfected. 
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Supplementary Fig. 1:  Supplementary data of donor/acceptor 
tandem fusion protein BRET assay and double-brilliance ßARR2 
biosensors shown in Fig. 1. (A) Expression of Myc-V2R and Flag-
MT1 in Fig. 1B was verified by western blot using anti-Myc and anti-
Flag antibodies. (B) Kinetics of AVP- and melatonin-promoted BRET 
changes of the indicated double-brilliance ßARR2 biosensors in HEK 
293T cells. AVP (V2R agonist) and melatonin (MT1 agonist) were used 
at 10µM.  NT, non-transfected.
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Supplementary Fig. 2: Supplementary data of the ßARR2 recruitment assay shown in Fig. 2.  BRET 
donor saturation curves for V2R-Rluc and V2R-Rluc8 were generated in HEK 293T cells in the presence 
of different N-Acceptor-ßARR2-C fusion constructs. BRET was measured 5 min after ligand addition. 
BRET was measured in the absence and presence of the V2R agonist AVP and V2R antagonist 
Vd(CH2)5[D-Tyr(Et)2, Ile4, Eda9]AVP. The absence of ligand-induced BRET in the presence of the 
antagonist demonstrates the specificity of the assay. Basal condition (); 0.1µM Vd(CH2)5[D-Tyr(Et)2, 
Ile4, Eda9]AVP (); 0.1µM AVP (); soluble RGFP (). 
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Supplementary Fig. 2:  Supplementary data of the ßARR2 recruitment assay 
shown in Fig. 2. (A) BRET donor saturation curves for V2R-Rluc and V2R-Rluc8 
were generated in HEK 293T cells in the presence of different N-Acceptor-ßARR2-C 
fusion constructs. BRET was measured 5 min after ligand addition. BRET was mea-
sured in the absence and presence of the V2R agonist AVP and V2R antagonist 
Vd(CH2)5[D-Tyr(Et)2, Ile4, Eda9]AVP. The absence of ligand-induced BRET in the 
presence of the antagonist demonstrates the specificity of the assay. Basal condi-
tion (l); 0.1µM Vd(CH2)5[D-Tyr(Et)2, Ile4, Eda9]AVP (l); 0.1µM AVP (m); soluble 
RGFP (o).
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Supplementary Fig. 3: Comparison of emitted light intensities of Rluc and Rluc8 fusion proteins. Rluc 
(A) and the indicated ßARR2 double-brilliance (B) and V2R (C) constructs were expressed in HEK 293T 
cells. Luciferase activity was determined in the presence of 5µM coelenterazine h (middle panels) and 
another aliquot submitted to western blot analysis (upper panels) using anti-Flag (A), anti-ßARR (B) and 
anti-Rluc (C) antibodies. Protein bands were quantified and luciferase activity of Rluc8 fusion proteins 
expressed as % of the corresponding Rluc fusion protein (lower panels). 
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Supplementary Fig. 3: Comparison of emitted light intensities of Rluc and 
Rluc8 fusion proteins. Rluc (A) and the indicated ßARR2 double-brilliance (B) and 
V2R (C) constructs were expressed in HEK 293T cells. Luciferase activity was deter-
mined in the presence of 5?M coelenterazine h (middle panels) and another aliquot 
submitted to western blot analysis (upper panels) using anti-Flag (A), anti-ßARR (B) 
and anti-Rluc (C) antibodies. Protein bands were quantified and luciferase activity of 
Rluc8 fusion proteins expressed as % of the corresponding Rluc fusion protein (lower 
panels).
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